DNMT3A and acute myeloid leukemia: In an intermediate risk AML cohort treated at Cleveland Clinic, DNMT3A, U2AF1 and EZH2 mutations were important prognostic factors for overall survival (OS) and relapse-free survival (RFS) 26.